Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer

International Journal of Clinical Oncology

Volumn 9, Issue 3, 2004, Pages 174-178

  Onoue, Masahide ^a   Terada, Tomohiro ^a   Okuda, Masahiro ^a   Fujimoto, Koji ^b   Doi, Ryuichiro ^b   Imamura, Masayuki ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Cancer chemotherapy; Gemcitabine; Leukopenia; Pancreatic cancer; Surgical resection

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 3142548818     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-004-0393-5     Document Type: Article

References (12)

1. Warshaw AL, Castillo CF-D (1992) Pancreatic carcinoma. N Engl J Med 326:455-465
2. Laethem J-LV, Demols A, Gay F, et al. (2003) Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Oncol Biol Phys 56:974-980
3. Burris HA III, Moore MJ, Andersen J, et al. (1997) Improvements in survival and clinical benefit with gemcitbine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
4. Haller DG (2003) Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 56:16-23
5. Okada S, Ueno H, Okusaka T, et al. (2001) Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 31:7-12
6. Onoue M, Kato T, Terada T, et al. (2003) Pharmaceutical care on pancreatic cancer chemotherapy. Appropriate usage of G-CSF (granulocyte colony-stimulating factor) for gemcitabine-induced leukopenia (in Japanese). Jpn J Pharm Health Care Sci 28:391-396
7. Marty M, Pouillart P, Scholl S, et al. (1990) Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821
8. Italian Group for Antiemetic Research (1992) Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in preventation of cisplatin-induced emesis. Lancet 340:96-99
9. Gabrilove JL, Jakubowski A, Scher H, et al. (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422
10. Goncalves A, Viret F, Ciccolini J, et al. (2003) Phase I and pharmacokinetic study of escalating dose of docetaxel administrated with granulocyte colony-stimulating factor support in adult advanced solid tumors. Clin Cancer Res 9:102-108
11. Steube KG, Meyer C, Drexler HG (1998) Secretion of functional hematopoietic growth factors by human carcinoma cell lines. Int J Cancer 78:120-124
12. Blumenthal RD, Reising A, Leon E, et al. (2002) Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancretic tumor lines. Clin Cancer Res 8:1301-1309